JPWO2020190990A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020190990A5 JPWO2020190990A5 JP2021556462A JP2021556462A JPWO2020190990A5 JP WO2020190990 A5 JPWO2020190990 A5 JP WO2020190990A5 JP 2021556462 A JP2021556462 A JP 2021556462A JP 2021556462 A JP2021556462 A JP 2021556462A JP WO2020190990 A5 JPWO2020190990 A5 JP WO2020190990A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- administered
- cancer cells
- checkpoint inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962819870P | 2019-03-18 | 2019-03-18 | |
| US62/819,870 | 2019-03-18 | ||
| PCT/US2020/023250 WO2020190990A1 (en) | 2019-03-18 | 2020-03-18 | Tumor-selective combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022525476A JP2022525476A (ja) | 2022-05-16 |
| JPWO2020190990A5 true JPWO2020190990A5 (es) | 2023-03-23 |
Family
ID=72519160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556462A Pending JP2022525476A (ja) | 2019-03-18 | 2020-03-18 | 腫瘍選択的併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220160703A1 (es) |
| EP (1) | EP3942061A4 (es) |
| JP (1) | JP2022525476A (es) |
| KR (1) | KR20220004025A (es) |
| CN (1) | CN113905763A (es) |
| AU (1) | AU2020240035A1 (es) |
| BR (1) | BR112021018545A2 (es) |
| CA (1) | CA3130513A1 (es) |
| MX (1) | MX2021011301A (es) |
| WO (1) | WO2020190990A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230128175A (ko) * | 2022-02-25 | 2023-09-04 | 주식회사 온코크로스 | 루복시스타우린을 포함하는 항암용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE037382T2 (hu) * | 2010-09-22 | 2018-08-28 | Univ Texas | Eljárás rák kezelésére targeting NQOl alkalmazásával |
| CA2909091C (en) * | 2013-04-09 | 2021-11-02 | The Board Of Trustees Of The University Of Illinois | Tumor-selective combination therapy |
| EP3334465A1 (en) * | 2015-08-12 | 2018-06-20 | Bayer Pharma Aktiengesellschaft | Pharmaceutical combination for the treatment of cancer |
| SG11201808306PA (en) * | 2016-03-24 | 2018-10-30 | Tragara Pharmaceuticals Inc | Treatment of cancer with tg02 |
| KR20240006698A (ko) * | 2017-07-21 | 2024-01-15 | 제넨테크, 인크. | 암에 대한 치료 및 진단 방법 |
-
2020
- 2020-03-18 MX MX2021011301A patent/MX2021011301A/es unknown
- 2020-03-18 US US17/440,787 patent/US20220160703A1/en active Pending
- 2020-03-18 CA CA3130513A patent/CA3130513A1/en active Pending
- 2020-03-18 JP JP2021556462A patent/JP2022525476A/ja active Pending
- 2020-03-18 KR KR1020217033464A patent/KR20220004025A/ko unknown
- 2020-03-18 AU AU2020240035A patent/AU2020240035A1/en active Pending
- 2020-03-18 WO PCT/US2020/023250 patent/WO2020190990A1/en unknown
- 2020-03-18 EP EP20773832.9A patent/EP3942061A4/en active Pending
- 2020-03-18 BR BR112021018545A patent/BR112021018545A2/pt unknown
- 2020-03-18 CN CN202080037114.7A patent/CN113905763A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway | |
| RU2480211C2 (ru) | Лечение рака молочной железы с помощью соединения 4-иод-3-нитробензамид в комбинации с противоопухолевыми средствами | |
| US20210069147A1 (en) | Pharmaceutical combination and uses thereof | |
| EP3638228B1 (en) | Compounds for treating tnbc | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| JP7192011B2 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| JP2020530467A (ja) | 癌転移を処置するためにキナーゼを標的とする方法 | |
| KR20190135028A (ko) | 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용 | |
| US20200323820A1 (en) | Materials and methods for inhibiting tumor growth | |
| JP2018531273A6 (ja) | がんを治療するためのｍｄｍ２阻害剤の投与計画 | |
| KR20220086627A (ko) | 카페시타빈 및 트라스투주맙과 조합으로 투카티닙을 사용하여 her2 양성 유방암을 치료하는 방법 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| US11583509B2 (en) | Compound for treating cancer and diabetes | |
| JPWO2020190990A5 (es) | ||
| Ranji et al. | Nanobiotechnological approaches to overcome drug resistance in breast cancer | |
| Lu et al. | Exploring the therapeutic potential of ADC combination for triple-negative breast cancer | |
| Cao et al. | A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer | |
| JP7125059B2 (ja) | ｕＰＡＲＡＰを標的にする抗体薬物複合体 | |
| US7977320B2 (en) | Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents | |
| RU2021129882A (ru) | Избирательная для опухоли комбинированная терапия | |
| US20240124610A1 (en) | Methods for treating her2-negative or her2-low cancer | |
| US20230365673A1 (en) | Means for reducing radio- and chemotherapy resistance and adverse effects | |
| Arnold et al. | Innovative therapeutic strategies to overcome radioresistance in breast cancer | |
| WO2016179702A1 (en) | Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers |